Literature DB >> 23943023

Rational study endpoint(s) for preoperative trials in pancreatic cancer: pathologic response rate, margin negative resection, overall survival or 'all of the above'?

Gauri R Varadhachary1, Douglas B Evans.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23943023     DOI： 10.1245/s10434-013-3165-5

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   5.344


× No keyword cloud information.
  3 in total

Review 1.  Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification.

Authors:  J W Gilbert; B Wolpin; T Clancy; J Wang; H Mamon; A B Shinagare; J Jagannathan; M Rosenthal
Journal:  Ann Oncol       Date:  2017-09-01       Impact factor: 32.976

2.  Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.

Authors:  Matthew H G Katz; Qian Shi; Syed A Ahmad; Joseph M Herman; Robert de W Marsh; Eric Collisson; Lawrence Schwartz; Wendy Frankel; Robert Martin; William Conway; Mark Truty; Hedy Kindler; Andrew M Lowy; Tanios Bekaii-Saab; Philip Philip; Mark Talamonti; Dana Cardin; Noelle LoConte; Perry Shen; John P Hoffman; Alan P Venook
Journal:  JAMA Surg       Date:  2016-08-17       Impact factor: 14.766

3.  Neoadjuvant therapy is associated with lower margin positivity rates after Pancreaticoduodenectomy in T1 and T2 pancreatic head cancers: An analysis of the National Cancer Database.

Authors:  Stephanie H Greco; David A August; Mihir M Shah; Chunxia Chen; Dirk F Moore; Monika Masanam; Amber L Turner; Salma K Jabbour; Parisa Javidian; Miral S Grandhi; Timothy J Kennedy; H Richard Alexander; Darren R Carpizo; Russell C Langan
Journal:  Surg Open Sci       Date:  2020-12-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.